On Demand 2018 Literature Review

You can earn up to 6.5 AMA PRA Category 1 Credit(s)TM.

Price: $99 College members, $125 non-members

To help you keep abreast of the latest clinical developments in allergy and immunology, ACAAI will continue its highly successful Literature Review program. It's a review of the most important, clinically-focused literature of our specialty published between November 2017 and October 2018, with an emphasis on clinical relevance. Faculty includes allergy-immunology training program directors and specialists in practice.

Copies of the spiral-bound, printed syllabus are available for purchase HERE.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 



Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Discuss recent advances in basic science that are relevant to allergy and immunology. 
  • Describe recent developments in rhinitis and sinusitis. 
  • Recognize the clinical presentation of activated phosphoinositide 3-kinase delta syndrome and distinguish it from common variable immunodeficiency.
  • Better diagnose and manage asthma and COPD.
  • Discuss important scientific and clinical advances in the pathophysiology and treatment of urticaria, angioedema and other skin disorders. 
  • Summarize the role of the microbiome in human atopic diseases. 
  • Identify new concepts in anaphylaxis, drug allergy and stinging insect hypersensitivity, as well as utilize clinically relevant findings in these areas.
  • Describe recent developments in immunotherapy.
  • Discuss recent developments in food allergy.
  • Better counsel patients on environmental factors that may impact respiratory and allergic disease; and better recognize, diagnose and manage occupational allergic diseases.
  • Apply practical lessons learned from recent literature in pediatric allergy, asthma and immunology.
  • Apply practical lessons learned from recent literature in allergy, asthma and immunology.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Specific disclosure information for the 2018 Annual Meeting is now available online.

All identified conflicts of interest have been resolved.

Chitra Dinakar, MD, FACAAI
Advisory Committee
Honorarium/Unrestricted Research Award: DBV Technologies

Matthew Greenhawt, MD, MBA, MSc, FACAAI
Advisory Committee
Honorarium: Aimmune Therapeutics, Inc., DBV Technologies, Kaleo Pharmaceuticals, Nutricia

David A. Khan, MD, FACAAI
Advisory Committee
Consulting, Fee: Aimmune Therapeutics, Inc.
Speaker, Honorarium: Genentech

James T. Li, MD, PhD, FACAAI
Consulting, Fee: GlaxoSmithKline

Anthony Montanaro, MD, FACAAI
Clinical Investigator, Contracted Research: Genentech, GlaxoSmithKline, Merck, Novartis, Regeneron, Sanofi, Stallergenes, Teva

Harold S. Nelson, MD, FACAAI
Consulting, Fee: ALK, Pearl Therapeutics

Anju T. Peters, MD
Clinical Investigator, Contracted Research: AstraZeneca
Consulting, Fee: Sanofi

Marc A. Riedl, MD, MS
Consulting, Fee: Biocryst, CSL Behring, Hycor, Pharming Group, Shire
Clinical Investigator, Contracted Research: Biocryst, CSL Behring, Shire
Speaker, Honorarium: CSL Behring, Pharming Group, Shire

John M. Routes, MD, FACAAI
Clinical Investigator, Contracted Research: AstraZeneca, CSL Behring

The following have no financial relationships to disclose:

Mark S. Dykewicz, MD, FACAAI
Mitchell H. Grayson, MD, FACAAI
John M. Kelso, MD, FACAAI



Course summary
Available credit: 
  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 Attendance
Course opens: 
Course expires: 

Chitra Dinakar, MD, FACAAI, is a clinical professor and clinical chief of allergy & asthma at Stanford University School of Medicine. She is an ABAI director, AAAAI board director, Joint Task Force on Practice Parameters member, and a former regent of the ACAAI Board. She has authored over 100 publications, is the associate editor of AllergyWatch, and on the editorial board of the Annals of Allergy, Asthma and Immunology and Allergy and Asthma Proceedings. She is a recipient of the College’s Woman in Allergy and Distinguished Fellow awards, and the Acellus Teacher of the Year award.


Mark S. Dykewicz, MD, FACAAI, is Raymond & Alberta Slavin-Endowed Professor in Allergy & Immunology, chief of allergy and immunology, professor of internal medicine and fellowship program director at Saint Louis University.  A past recipient of the ACAAI Distinguished Service Award and the AAAAI Special Recognition Award, and author of >150 publications, his past service includes terms on the board of directors of the ABAI and AAAAI and Chair of the FDA Pulmonary Allergy Drug Advisory Committee.


Mitchell H. Grayson, MD, FACAAI, is the director of the Division of Allergy and Immunology, Nationwide Children's Hospital and professor of pediatrics, The Ohio State University, Columbus OH. He received his MD from the University of Chicago, undertook an internal medicine residency at the Hospital of the University of Pennsylvania, and completed an allergy-immunology fellowship at Johns Hopkins University. He is an NIH-funded investigator studying the role of viruses in the development of allergic disease and asthma. He serves as the associate editor of the Annals of Allergy, Asthma, and Immunology, and is on the Board of Directors for the ABAI and the AAAAI.


Matthew Greenhawt, MD, MSc, MBA, FACAAI, is an Associate Professor with the Department of Pediatrics’ Allergy Section, Children’s Hospital Colorado and the University of Colorado School of Medicine and the Director of the Children’s Hospital Colorado Food Challenge and Research Unit. He holds an MD and MBA from Tufts University, and a master’s of science degree in health and healthcare policy from the University of Michigan, Rackham School of Graduate Studies.  He is an associate editor for the Annals of Allergy, Asthma and Immunology, a member of the Joint Taskforce on Allergy Practice Parameters, and chair of the ACAAI Food Allergy Committee. He is an AHRQ-funded researcher studying comparative effectiveness and decision-science.


John M. Kelso, MD, FACAAI, completed fellowship training at the Mayo Clinic. He is on staff at Scripps Clinic in San Diego and is a clinical professor at the University of California San Diego. He has served on the Board of Directors of the ABAI and the AAAAI. He has authored over 100 publications, served on numerous editorial boards and is a frequent national and international speaker.


David A. Khan, MD, FACAAI, is professor of medicine and pediatrics at the University of Texas Southwestern Medical Center in Dallas. He is the program director for the allergy-immunology fellowship program at Southwestern. He has over 120 peer-reviewed publications. His clinical and research interests include drug allergy, refractory chronic urticaria, rush immunotherapy, and the interaction of depression and asthma.


James T. Li, MD, PhD, FACAAI, is professor of medicine and a previous chair of the Division of Allergic Diseases at Mayo Clinic Rochester. He is director of the allergy-immunology training Program at Mayo. Dr Li is a past president of the American Academy of Allergy Asthma and Immunology (AAAAI). Previous appointments include chair, ABAI; chair, Pulmonary and Allergy Drug Advisory Committee (FDA); and chair, RRC for Allergy and Immunology.


Anthony Montanaro, MD, FACAAI, was born and raised in Seattle where he attended the University of Washington to complete his undergraduate and medical studies. Following his internal medicine residency, he completed fellowships in rheumatology and allergy-immunology. He subsequently joined the faculty at the Oregon Health and Sciences University where he has been chair of allergy and immunology for over twenty years. He has devoted his career to patients, research and teaching.


Harold S. Nelson, MD, FACAAI, received his doctor of medicine degree from Emory University. He completed a fellowship in allergy/immunology at the University of Michigan. He is currently professor of medicine at National Jewish Health and the University of Colorado Denver School of Medicine.


Anju T. Peters, MD, completed her medical degree at University of Michigan after finishing undergraduate studies at Ohio State University. The rest of her training was completed at Northwestern University Feinberg School of Medicine including a residency in internal medicine and fellowship in allergy-immunology. After fellowship she joined the Division of Allergy & Immunology at Northwestern and currently is professor of medicine and director of clinical research.  She is a co-editor in chief of the Journal of Rhinology and Allergy and is on the editorial board of the Journal of Precision Respiratory Medicine.


Marc A. Riedl, MD, MS, is professor of medicine and clinical director of the US HAEA Angioedema Center at the University of California-San Diego where he serves as training program director for the allergy-immunology fellowship program. He received his medical degree from the University of Chicago–Pritzker School of Medicine, completed internal medicine residency at Barnes-Jewish Hospital of Washington University, and fellowships in clinical immunology & allergy and clinical pharmacology at UCLA. He serves on appointed expert panels for the FDA and NlH, and directs a clinical research program at UCSD focused on angioedema and immunodeficiency conditions.


John M. Routes, MD, FACAAI, is the section chief of allergy and clinical immunology in the Department of Pediatrics at Medical College of Wisconsin (MCW). Dr. Routes was the president of the Clinical Immunology Society (CIS) in 2013 and in 2016 received the CIS Distinguished Service Award. He was the principal investigator for the first statewide program (Wisconsin) to screen all newborns for severe combined immunodeficiency. He currently is the Chair of the NIH study section entitled “Investigations on Primary Immunodeficiency”.

Available Credit

  • 6.50 AMA PRA Category 1 Credit™
  • 6.50 Attendance


Please login or create an account to take this course.